Status: Not yet recruiting
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Participants needed: 5
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of MiamiUpdated: Jun 18, 2026Locations: 1
Eligibility criteria
worsening respiratory symptoms; [+6]
Active, untreated bacterial, mycobacterial or fungal infection [+5]